Floatz logo

Promitil

Gastro-Intestinal Intraepithelial Neoplasia

Lipomedix Pharmaceuticals Inc.Phase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Gastro-Intestinal Intraepithelial Neoplasia cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BB
9-valent human papillomavirus recombinant vaccine
Xiamen University
Phase 3B
Abi-1968
Antiva Biosciences
Phase 1NR

Same molecule, other indications

Promitil is also rated in:

ovarian cancerDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
42 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →